Share this page:

Pharmacy Fees for PrescribeIT to Begin January 1, 2025

Fees for pharmacists iStock 1363522669

Learn about the new fee structure and find answers to your questions.

Canada Health Infoway, a federally funded not-for-profit organization, developed and now operates PrescribeIT, Canada’s leading e-prescribing solution. Infoway works with governments, health care organizations, clinicians and patients to make health care more digital in order to facilitate faster, more seamless and secure information sharing. For the past seven years, PrescribeIT® has been sustained by start-up funding from Health Canada. However, to ensure its continued advancement and alignment with evolving healthcare needs, Infoway will introduce a nominal pharmacy transaction fee.

Background

Starting January 1, 2025, Canada Health Infoway will introduce a transaction fee of $0.20 for each new and renewed electronic prescription processed through PrescribeIT®. This fee will help to ensure the continued operation of PrescribeIT®, providing pharmacies across Canada with a reliable and secure e-prescription service. The fee will be the same for all pharmacies – both for independents as well as chain/banner retailers. Should you have any questions about the pharmacy transaction fee or wish to discuss your PrescribeIT® services further, you may contact us This email address is being protected from spambots. You need JavaScript enabled to view it..

Frequently Asked Questions

Infoway works with governments, health care organizations, clinicians and patients to make health care more digital in order to facilitate faster, more seamless and secure information sharing.

As a federally funded not-for-profit organization, Infoway is accountable to its Board of Directors and the Members of the Corporation which is made of Canada’s 14 federal, provincial and territorial deputy ministers of health ensuring its work aligns with the needs and priorities of Canada's health care system.

As part of its commitment to enhancing digital health, Infoway lead the implementation of PrescribeIT®, a national e-prescribing service. For the past seven years, PrescribeIT® has been sustained by start-up funding from Health Canada. Beginning January 2025, Infoway will introduce a fee to support the continued operations of PrescribeIT®. Infoway is not funded through transaction fees associated with PrescribeIT®.

PrescribeIT's self-sustainability model has always been based on transaction fees paid by pharmacies. Health Canada provided funding for the development of the technology and startup operations. This non-repayable seed capital also helped offset the costs of the service over time.

After providing a seven-year fee holiday, a $0.20 pharmacy transaction fee will be introduced for new and renewed prescriptions beginning January 1, 2025.

Infoway continues to be in conversation with government stakeholders, pharmacies, pharmacy associations, and other health care stakeholders to ensure all stakeholders understand the path forward and experience minimal disruption to their use of PrescribeIT®.

A "Billable Transaction” refers to a prescription (molecule, OTC or device) that was delivered through PrescribeIT® to the pharmacy through one of the following methods:

  1. The pharmacy receives a prescription from a prescriber into the pharmacy management system.
  2. The pharmacy receives a prescription printout or fax and retrieves a deferred prescription from PrescribeIT®.
  3. PrescribeIT® delivers a prescription by fax to the pharmacy (for example, where an error that necessitates a fail-over to fax).

Other functionalities, such as clinical communications, will continue to be provided free of charge.

Pharmacies will receive an electronic invoice each month covering all Billable Transactions for that billing period. All account, billing, and payment information will be available in a secure client portal for convenience and security.

Over the past seven years, PrescribeIT® has become the most advanced example of pan-Canadian interoperable digital health care.

PrescribeIT® improves patient safety by enhancing the effectiveness of virtual care and enabling the secure sharing of patient information among clinicians. PrescribeIT® also simplifies the authentication of opioids and controlled substances, reducing the risk of errors and misuse. These features help streamline clinical workflows, making healthcare delivery safer and more efficient.

Also, as a critical partner to governments across Canada, PrescribeIT® supports provinces and territories achieve critical health priorities by reducing costs, improving patient privacy and building equitable access to health care in rural and Indigenous communities.

The Evolution of PrescribeIT®

Our team at Infoway continues to be in conversation with government stakeholders, pharmacies, pharmacy associations, and other health care stakeholders to ensure all stakeholders understand the path forward and experience minimal disruption to their use of PrescribeIT®.

As part of our continued efforts to enhance Connected Care and meet evolving healthcare needs, Infoway is actively exploring new pathways to ensure the continued advancement of e-prescribing across the country.

In May 2024, Infoway launched a formal Request for Expression of Interest (RFEOI) to identify potential partners who could champion e-prescription innovation, increase service adoption, and maintain a low-cost structure to benefit all PrescribeIT® users.

The RFEOI also sought to identify partners who would seek alignment with jurisdictional strategies to advance Connected Care while addressing the unique needs of each region. We are excited about the new ideas and potential partnerships this process will help generate as we all work together towards the goal of ensuring better health outcomes for Canadians.

Infoway is committed to transparency and will keep you informed and updated about our progress and any relevant changes.

Should you have any questions about the pharmacy transaction fee or wish to discuss your PrescribeIT® services further, please contact us.

This email address is being protected from spambots. You need JavaScript enabled to view it.